Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Tumori|March 11, 2011
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM)Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profilePaolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2018
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumabPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal of the American Academy of Dermatology|June 9, 2009
Clinical genetic testing for familial melanoma in Italy: a cooperative studyWilliam Bruno, Paola Ghiorzo, Linda Battistuzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Tumori|March 11, 2011
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM)Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profilePaolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2018
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumabPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2022
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]Alice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal of the American Academy of Dermatology|June 9, 2009
Clinical genetic testing for familial melanoma in Italy: a cooperative studyWilliam Bruno, Paola Ghiorzo, Linda Battistuzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Pageof 13